Press Release: Sanofi to acquire Dren Bios bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell…
Tevogen Bios First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
600% higher market cap per team member when compared to industry average.…
Tevogen Bio’s Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
WARREN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio…